#CSL has licensed rights to a potentially first-in-class #anticlaudin1 #antibody developed by #AlentisTherapeutics in a #deal that could be worth up to $1.55 billion.
@pharmaphorum.bsky.socialExplore
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#CSL has licensed rights to a potentially first-in-class #anticlaudin1 #antibody developed by #AlentisTherapeutics in a #deal that could be worth up to $1.55 billion.